Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Levodopa/Benserazide vs Madopar in Parkinson's Disease
NCT02741947Phase 4Completed
- Sponsor
- Fondazione San Raffaele Monte Tabor
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of levodopa + benserazide in Parkinson's disease (PD) (2 arms), sponsored by Fondazione San Raffaele Monte Tabor. Primary endpoints: Area Under the Curve at 8 weeks and Unified Parkinson's Disease Rating Scale Part III at 8 weeks. Started Apr 2014; status: completed.
02
Drugs
levodopa + benserazide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02741947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741947.